AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19211442
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg of aspirin
Trial: 15026612
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of aspirin (AIS subgroup)
Trial: 8993489
Drug: Tacrine (80,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine (80, 120, or 160 mg/day)
Trial: 8226485
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 5 mg/kg
Trial: 23302821
Drug: Acupressure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure treatment (9-minute daily for 4 weeks)
Trial: 19034054
Drug: Combined vaginal
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combined vaginal and oral low‐dose estrogen plus progestogen therapy (EPT)
Trial: 17452842
Drug: Liposomal melanin
RxNorm normalized name: melanin synthetic (tyrosine, peroxide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal melanin spray (Lipoxome) with 3 cycles of 800 nm diode laser at intervals of 8 weeks (28-40 J/cm)
Trial: 17452842
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline spray before diode laser treatment
Trial: 15050312
Drug: Amifostine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (500 mg i.v. 20‐30 min before treatment the first 2 days of each week)
Trial: 15050312
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (thoracic RT plus oral etoposide and cisplatin without amifostine)
Trial: 17196507
Drug: 1 mg/day
RxNorm normalized name: Lyllana 0.1 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/day finasteride
Trial: 2145236
Drug: Enoximone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (1 mg/kg bolus, every 8 hours for 48 hours)
Trial: 2145236
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (frusemide, nitrates, dopamine‐dobutamine)
Trial: 438356
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg loperamide HCl (syrup formulation)
Trial: 438356
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg loperamide HCl (capsule formulation)
Trial: 438356
Drug: Comparative analysis
RxNorm normalized name: Chemicals and reagents for analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparative analysis of syrup and capsule formulations
Trial: 438356
Drug: Excretion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excretion of unchanged loperamide
Trial: 30267699
Drug: Fluorometholone 0.1%
RxNorm normalized name: FLUOROMETHOLONE 0.1% OINT,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorometholone 0.1% twice daily for 4 weeks
Trial: 30267699
Drug: Fluorometholone 0.1%
RxNorm normalized name: FLUOROMETHOLONE 0.1% OINT,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorometholone 0.1% four times daily for 4 weeks
Trial: 30267699
Drug: Fluorometholone 0.1%
RxNorm normalized name: FLUOROMETHOLONE 0.1% OINT,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorometholone 0.1% four times daily for 8 weeks
Trial: 28853994
Drug: Whole red
RxNorm normalized name: red mulberry whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole red grape juice (150 ml for men and 100 ml for women)
Trial: 25955226
Drug: PTH (1-84)
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PTH (1-84) 100 μg/d
Trial: 21856809
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (2-g loading dose followed by 500 mg every 12 hours)
Trial: 15114031
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin therapy (RPL-IVIg); 500 mg IVIg/kg/month
Trial: 4940157
Drug: Immunotherapy (B.C.G.)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (B.C.G.)
Trial: 12628840
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment
Trial: 31332110
Drug: Single-pass technique
RxNorm normalized name: MED PASS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-pass technique for lenticule preparation
Trial: 31332110
Drug: Double-pass technique
RxNorm normalized name: MED PASS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-pass technique for lenticule preparation
Trial: 26102258
Drug: Medicine Ball
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine Ball Training (MBT)
Trial: 27541380
Drug: Rosuvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (20 mg/day)
Trial: 22967451
Drug: EC-T (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC-T (epirubicin 90 mg/m², cyclophosphamide 600 mg/m² for 4 cycles, followed by docetaxel 80 mg/m² for 4 cycles)
Trial: 22967451
Drug: TP (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP (docetaxel 75 mg/m², carboplatin AUC = 5 for 6 cycles)
Trial: 16039494
Drug: Topical pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical pilocarpine 4%
Trial: 12460124
Drug: Cannabis Youth
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis Youth Treatment (CYT) study
Trial: 12460124
Drug: Marijuana Treatment
RxNorm normalized name: Marijuana
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marijuana Treatment Project (MTP)
Trial: 9877359
Drug: Td vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Td vaccine in Grade 6 students
Trial: 9877359
Drug: Td vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Td vaccine in Grade 9 students
Trial: 7795925
Drug: Ondansetron (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (4 mg orally)
Trial: 2612430
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A - standard brief description of upper G-I endoscopy
Trial: 359245
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg codeine phosphate 4-times daily
Trial: 26386383
Drug: Endoscopic repair
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic repair of OSB using a biocellulose patch
Trial: 24968955
Drug: COT1 (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COT1 (45 hours of conventional occupational therapy)
Trial: 24968955
Drug: COT2 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COT2 (80 hours of conventional occupational therapy)
Trial: 24968955
Drug: FES +
RxNorm normalized name: Ferric Ethylenediamine Tetraacetic Acid (Ferric EDTA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FES + COT (40 hours of COT therapy + 40 hours of FES therapy)
Trial: 16102611
Drug: Endovascular Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular Therapy (ET)
Trial: 11957554
Drug: Daily regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily regimen (2HRZ/2HR) - 2 months of isoniazid (H), rifampicin (R) and pyrazinamide (Z), followed by 2 months of H and R
Trial: 11957554
Drug: Combined regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined regimen (2HRZ/2H3R3) - 2 months of HRZ, followed by H and R given 3 times weekly for 2 months or 4 months if initial sputum specimens were culture positive
Trial: 7137874
Drug: Conventional metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional metoprolol 100 mg twelve hourly
Trial: 7137874
Drug: Metoprolol S.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol S.A. (slow release formulation) once daily
Trial: 7137874
Drug: Oxprenolol S.R.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxprenolol S.R. (slow release formulation) once daily
Trial: 31182369
Drug: Inhaled eluforsen
RxNorm normalized name: Eluforsen
DrugBank: Eluforsen (DB16154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled eluforsen (up to 50 mg, dosed 3 times per week for 4 weeks)
Trial: 24438599
Drug: Dexmedetomidine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1.0 μg/kg intravenously for 10 minutes, maintained with 0.4 μg/kg and modulated from 0.2 to 0.7 μg/kg/hour in ICU
Trial: 24438599
Drug: Propofol 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.1 mg/kg intravenously for 10 minutes, maintained with 1 to 2 mg/kg/hour in recovery room and ICU
Trial: 23062388
Drug: Allergen immunotherapy
RxNorm normalized name: Allergen immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen immunotherapy with higher serum level of 25(OH)D
Trial: 23062388
Drug: Allergen immunotherapy
RxNorm normalized name: Allergen immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen immunotherapy with 25(OH)D serum level higher than 30 ng/mL
Trial: 17635283
Drug: Infusion group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion group (pantoprazole 80 mg i.v. bolus followed by continuous infusion of 8 mg/h for 3 days)
Trial: 17635283
Drug: Bolus group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus group (pantoprazole 80 mg i.v. bolus followed by 40 mg i.v. bolus every 12 h for 3 days)
Trial: 17635283
Drug: No-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment group (no acid suppression in the first 3 days)
Trial: 17635283
Drug: Infusion group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion group vs Bolus group
Trial: 7791015
Drug: Intracervical 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical 0.5 mg PGE2 gel
Trial: 7791015
Drug: Intravaginal 3
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal 3 mg PGE2 tablet
Trial: 30916733
Drug: Drug-deactivation bag
RxNorm normalized name: obecabtagene autoleucel
DrugBank: Obecabtagene autoleucel (DB17362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-deactivation bag
Trial: 29176768
Drug: Open administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open administration of expressive writing intervention
Trial: 29176768
Drug: Hidden administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hidden administration of expressive writing intervention
Trial: 23514584
Drug: Temsirolimus monotherapy
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus monotherapy (25 mg weekly)
Trial: 23514584
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (irinotecan 180 mg/m2 biweekly + temsirolimus)
Trial: 8915019
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment on a non-adjacent tooth with persistent or recurrent periodontitis
Trial: 1856141
Drug: Amikacin 15
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin 15 mg/kg/day given as a single dose
Trial: 1856141
Drug: Amikacin 15
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin 15 mg/kg/day given in two divided doses at 12‐h intervals
Trial: 6349646
Drug: Meclofenamate sodium,
RxNorm normalized name: Meclofenamate Sodium, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclofenamate sodium, 200 mg/day
Trial: 6349646
Drug: Meclofenamate sodium,
RxNorm normalized name: Meclofenamate Sodium, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclofenamate sodium, 300 mg/day
Trial: 6349646
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA), 3.6 g/day
Trial: 29947474
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg orally disintegrating film
Trial: 29947474
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg film-coated tablets (Viagra®, Pfizer, Mexico)
Trial: 28438118
Drug: Rifampicin-based regimens
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin-based regimens (R10, 15 and 20 mg/Kg)
Trial: 19247202
Drug: CIFN induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIFN induction therapy (27 or 18 mg q.d.)
Trial: 11577792
Drug: Postoperative chemoradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative chemoradiation therapy
Trial: 11577792
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy or chemoradiation
Trial: 11577792
Drug: Various chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various chemotherapy regimens
Trial: 9205931
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (nitrendipine 10-40 mg/day, possibly with enalapril 5-20 mg/day and/or hydrochlorothiazide 12.5-25 mg/day)
Trial: 8035470
Drug: Therapeutic self-disclosure
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic self-disclosure in couples during 10 weekly sessions
Trial: 29957868
Drug: Camicinal 50
RxNorm normalized name: Camicinal
DrugBank: Camicinal (DB12567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camicinal 50 mg daily for a maximum of 7 days
Trial: 23721984
Drug: Combination program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination program (yoga therapy and lifestyle modification)
Trial: 18362654
Drug: Topical mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical mitomycin C (MMC) 0.2 mg/mL
Trial: 12760984
Drug: Acetaminophen 10
RxNorm normalized name: acetaminophen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 10 mg/kg orally (Control)
Trial: 12760984
Drug: Acetaminophen 10
RxNorm normalized name: acetaminophen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 10 mg/kg with 1 mg/kg of codeine orally
Trial: 12760984
Drug: Transnasal butorphanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transnasal butorphanol 25 micro g/kg given immediately after the induction of anesthesia
Trial: 12760984
Drug: Ketorolac 1
RxNorm normalized name: ketorolac 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 1 mg/kg given IM immediately after the induction of anesthesia
Trial: 1425888
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine system (TNS) 30 cm2
Trial: 6377487
Drug: Exposure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure treatment until day 14 post-burn, followed by excision and grafting of non-spontaneously healed areas (group E, 76 patients)
Trial: 24852569
Drug: Oral UDCA
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral UDCA treatment (ursodeoxycholic acid) after esophageal perfusion with DCA (250 μM) for 8 weeks
Trial: 22058145
Drug: UDCA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA treatment
Trial: 15807285
Drug: Repaglinide (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (1.0 mg tid)
Trial: 15807285
Drug: Nateglinide (90.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (90.0 mg tid)
Trial: 12040357
Drug: 1800 mg
RxNorm normalized name: glycerin 1800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg of WS 1442
Trial: 12040357
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg of WS 1442
Trial: 17007849
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg anastrozole
Trial: 15998903
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tamoxifen and anastrozole
Trial: 497090
Drug: Pivampicillin tablets
RxNorm normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin tablets
Trial: 497090
Drug: Pivampicillin capsules
RxNorm normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin capsules
Trial: 497090
Drug: Pivampicillin capsules
RxNorm normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin capsules and tablets
Trial: 29668860
Drug: Chemotherapy (pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2, both every 3 weeks)
Trial: 18405147
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and medication
Trial: 18405147
Drug: Medication (Methyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (Methyl vitamin B12 250 microg, once daily)
Trial: 2686956
Drug: Beclobrate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclobrate (100 mg)
Trial: 8735678
Drug: Bezafibrate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (400 mg)
Trial: 7884019
Drug: Amitriptyline 150
RxNorm normalized name: amitriptyline 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 150 mg per day
Trial: 31907004
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C) continuing with standardized treatment schedule of MTX 15 mg/week
Trial: 30418115
Drug: Oral steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroid or nbDMARD use
Trial: 30418115
Drug: Reason for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reason for not modifying therapy
Trial: 25403846
Drug: Ibandronate treatment
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate treatment for 3 years
Trial: 19459079
Drug: Superoxidized solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superoxidized solution (SOS)
Trial: 17299118
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and exercise intervention (3-month duration, daily energy deficit of -45.7 +/- 12.4%)
Trial: 9808499
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (GCV) 1000 mg every 8 hr for CrCl >50 ml/min
Trial: 9808499
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (GCV) 1000 mg every 24 hr for CrCl of 25-50 ml/min
Trial: 9808499
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (GCV) 500 mg every day for CrCl of 10-24 ml/min
Trial: 9808499
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir (GCV) 500 mg every other day after dialysis for CrCl <10 ml/min
Trial: 9808499
Drug: Absolute bioavailability
RxNorm normalized name: Honey Absolute
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absolute bioavailability of oral GCV
Trial: 8694983
Drug: Oscillating/rotating electric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oscillating/rotating electric toothbrush (Braun Oral‐B Plaque Remover)
Trial: 189655
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with vincristine and actinomycin D for 6 months
Trial: 189655
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with vincristine and actinomycin D for 15 months